View the Edison Group Research Report on Incannex here https://www.edisongroup.com/publication/addressing-unmet-needs-via-alternative-approach/31265/ ---------------------------- Interesting to note that the valuation is based on the US Market penetration alone and... "We ascribe 92% of the company’s valuation to IHL-42X, 1% to psilocybin and 7% to cash. We have not included the earlier-stage assets IHL-675A or IHL-216A in our valuation; however, we will revisit our valuation following clinical progression of these therapies."
--------------------------- GLAH (looking forward to Top 20 shareholder update)
IHL Price at posting:
23.5¢ Sentiment: Buy Disclosure: Held
